Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by University of California, San Diego.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
University of California, San Diego
Information provided by:
University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00265408
First received: December 12, 2005
Last updated: March 30, 2007
Last verified: March 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection.
| Condition | Intervention | Phase |
|---|---|---|
|
Ischemic Stroke Cervicocephalic Arterial Dissection |
Drug: aspirin Drug: warfarin |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection |
Resource links provided by NLM:
Further study details as provided by University of California, San Diego:
Primary Outcome Measures:
- Incidence of stroke by one year.
Secondary Outcome Measures:
- Recurrent dissection by one year.
- Incidence of TIA by one year.
- Incidence of major and minor bleeding episodes by one year.
| Estimated Enrollment: | 20 |
| Study Start Date: | December 2005 |
| Estimated Study Completion Date: | March 2007 |
20 patients with cervicocephalic arterial dissection will be randomized to open-label aspirin or warfarin, rate of stroke and adverse events will be endpoints.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical and imaging diagnosis of cervicocephalic arterial dissection within 3 months.
Exclusion Criteria:
- Any contraindication to aspirin or warfarin.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00265408
Locations
| United States, California | |
| UCSD Medical Center | |
| San Diego, California, United States, 92103 | |
Sponsors and Collaborators
University of California, San Diego
Investigators
| Principal Investigator: | Matt B Jensen, MD | UCSD Stroke Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00265408 History of Changes |
| Other Study ID Numbers: | UCSD IRB #051253 |
| Study First Received: | December 12, 2005 |
| Last Updated: | March 30, 2007 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Aneurysm, Dissecting Stroke Aneurysm Vascular Diseases Cardiovascular Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Aspirin Warfarin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics |
ClinicalTrials.gov processed this record on May 22, 2013